Volume 5.31 | Aug 8

Mammary Cell News 5.31 August 8, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Using cross-linking coimmunoprecipitation assays, scientists determined that AXL associated with epidermal growth factor receptor (EGFR), other ErbB receptor family members, hepatocyte growth factor receptor, and platelet-derived growth factor receptor but not insulin-like growth factor 1 receptor or insulin receptor. From these AXL interaction data, they predicted AXL-mediated signaling synergy for additional receptor tyrosine kinases and validated these predictions in cells. [Sci Signal] Abstract | Press Release
Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
PUBLICATIONS (Ranked by impact factor of the journal)

A Common Docking Domain in Progesterone Receptor-B Links DUSP6 and CK2 Signaling to Proliferative Transcriptional Programs in Breast Cancer Cells
Scientists describe an N-terminal common docking (CD) domain in progesterone receptor (PR)-B, a motif first described in mitogen-activated protein kinases. Binding studies revealed PR-B interacts with dual-specificity phosphatase 6 (DUSP6) via the CD domain. [Nucleic Acids Res] Full Article

Comprehensive Analysis of miRNA Targets in Breast Cancer Cells
Investigators systematically identified endogenous microRNA (miRNA) target genes by using AGO2 immunoprecipitation and microarray analyses in two breast cancer cell lines, MCF7 and MDA-MB-231, representing luminal and basal-like breast cancer, respectively. [J Biol Chem] Abstract | Full Article

Nuclear T-STAR Protein Expression Correlates with HER2 Status, Hormone Receptor Negativity and Prolonged Recurrence Free Survival in Primary Breast Cancer and Decreased Cancer Cell Growth In Vitro
The authors investigated the functional role of testis-signal transduction and activation of RNA (T-STAR) through survival analysis of patients with primary invasive breast cancer and experimental evaluation of the effect of T-STAR on breast cancer cell growth. [PLoS One] Full Article

Epigenetic Modifications of Prostate-Derived Ets Transcription Factor in Breast Cancer Cells
To date, no studies have been conducted to elucidate the epigenetic modifications of prostate-derived Ets factor (PDEF) in cancer progression. Using breast and prostate cancer cells, scientists investigated the effect of the methylation inhibitor 5′ azacytidine on the expression of PDEF in these cells. [Oncol Rep] Abstract

Systemic Alteration of Cell Surface and Secreted Glycoprotein Expression in Malignant Breast Cancer Cell Lines
Glycoproteins expressed by a group of cell lines originating from malignant tumors of the breast were compared to those expressed by a non-malignant set. [Glycobiology] Abstract

Crosstalk between PKCα and Notch-4 in Endocrine-Resistant Breast Cancer Cells
The authors tested whether PKCα overexpression affects Notch activity and whether Notch signaling contributes to endocrine resistance in PKCα-overexpressing breast cancer cells. [Oncogenesis] Full Article


Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Researchers sought to determine whether adjuvant tamoxifen treatment for breast cancer is associated with reduced contralateral breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. [J Clin Oncol]
| Press Release

CX3CL1 Expression Is Associated with Poor Outcome in Breast Cancer Patients
CX3CL1 expression was examined in a large cohort of breast cancers by immunohistochemistry and its association with clinicopathological factors, biomarker expression, and impact on patients’ survival was assessed. [Breast Cancer Res Treat] Abstract

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
Prior work has revealed a role of cytochrome and sulfotransferase enzymes in tamoxifen metabolism. In this descriptive study, correlations were examined between concentrations of tamoxifen metabolites and genotypes for CYP2D6, CYP3A4, CYP3A5, SULT1A1, SULT1A2 and SULT1E1 in 135 patients with estrogen receptor-positive breast cancer. [PLoS One] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
Platelets, Coagulation and Fibrinolysis in Breast Cancer Progression
This review provides a comprehensive overview of the evidence and mechanisms supporting the roles played by platelets, coagulation activation, and the fibrinolytic system in breast cancer progression. [Breast Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Susan G. Komen® Awards $3.6 Million in Grants to UNC and Duke for Breast Cancer Research in 2013
Susan G. Komen® announced $3.6 million in research funding to ten programs at the University of North Carolina (UNC) at Chapel Hill and Duke University. The grants are part of Komen’s $42 million 2013 national research portfolio. [North Carolina Triangle to the Coast Affiliate of Susan G. Komen®] Press Release

Baylor Receives $960,000 Plus in Komen Breast Cancer Grants
Four Baylor College of Medicine researchers received more than $960,000 in new grant funding from Susan G. Komen for the Cure to advance breast cancer research. [Baylor College of Medicine] Press Release

NICE Publishes Guidance on Tests Used during Surgery to Detect whether Breast Cancer Has Spread
The National Institute for Health and Care Excellence (NICE) has recommended a new test for surgeons to use during operations to discover if breast cancer has spread. The test – the RD-100i OSNA system produced by Sysmex UK – is used while surgery to remove breast cancer tumors is carried out. It can detect if the cancer has spread to lymph nodes in the armpit. [National Institute for Health and Care Excellence] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Based Assays
November 18-19, 2013
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Postdoctoral Fellow – Mammary Stem Cell (North Carolina Central University)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Postdoctoral Fellowship – Mechanism of Action of Drugs (Celgene Corporation)

Postdoctoral Fellow – Breast Cancer Research (Weizmann Institute of Science)

Postdoctoral Fellow – Breast Cancer Cell Research (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Fellow – Breast and Renal Cell Carcinoma Research (University of North Carolina – Chapel Hill)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us